Beta-2 microglobulin as a marker for HIV infection

Area of Science:

• Biochemistry
• Immunology
• Medical Diagnostics

Background:

• HIV infection detection is crucial for life insurance underwriting.
• Certain regulations restrict the use of direct HIV antibody tests for applicants.
• Surrogate markers are employed to assess HIV status indirectly.

Purpose of the Study:

• To evaluate Beta-2 microglobulin (B2M) as a sensitive surrogate marker for HIV infection.
• To compare the utility of B2M with T cell testing in life insurance contexts.
• To highlight the advantages of B2M in specific regulatory environments.

Main Methods:

• The study focuses on the biochemical and diagnostic properties of B2M.
• Comparative analysis of B2M and T cell testing as HIV surrogates.
• Assessment of B2M stability in serum samples.

Main Results:

• Beta-2 microglobulin demonstrates high sensitivity as an HIV surrogate marker.
• B2M exhibits significantly greater stability in serum over extended periods compared to T cell markers.
• This stability is advantageous for long-term storage and retrospective analysis.

Conclusions:

• Beta-2 microglobulin is a viable and stable surrogate test for HIV detection in life insurance.
• Its stability makes it a more practical option than T cell testing where direct HIV testing is prohibited.
• B2M facilitates HIV screening in regulated environments, ensuring applicant safety and insurer risk assessment.